drugset
drugset / Trial / NCT07311746

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

NCT07311746 ↗

Phase 1/2 Recruiting 36 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.

Timeline

Start
2026-04-28
Primary completion
2029-01-31
Completion
2031-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule — Other
Subject Ruxolitinib Small molecule — Oral
Subject Venetoclax Small molecule — Oral

Indications

T-cell prolymphocytic leukemia